Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Rand Ahmad, Samaneh Alaei & Hamid Omidian. (2018) Safety and performance of current abuse-deterrent formulations. Expert Opinion on Drug Metabolism & Toxicology 14:12, pages 1255-1271.
Read now
Read now
Laura Murphy, Karen WK Ng, Victoria CH Su, Sarah Woodworth-Giroux, Todd S Levy, Beth A Sproule & Andrea D Furlan. (2015) Approach to the pharmacological management of chronic pain in patients with an alcohol use disorder. Journal of Pain Research 8, pages 851-857.
Read now
Read now
Michael J Brennan. (2013) Update on prescription extended-release opioids and appropriate patient selection. Journal of Multidisciplinary Healthcare 6, pages 265-280.
Read now
Read now
Jeffrey A. Gudin, Shanthi Mogali, Jermaine D. Jones & Sandra D. Comer. (2013) Risks, Management, and Monitoring of Combination Opioid, Benzodiazepines, and/or Alcohol Use. Postgraduate Medicine 125:4, pages 115-130.
Read now
Read now
Jeffrey A. Gudin. (2013) Assessment of Extended-Release Opioid Analgesics for the Treatment of Chronic Pain. Journal of Pain & Palliative Care Pharmacotherapy 27:1, pages 49-61.
Read now
Read now
Laura M Lourenço, Michele Matthews & Robert N Jamison. (2013) Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use?. Expert Opinion on Drug Delivery 10:2, pages 229-240.
Read now
Read now
John H. Peniston. (2012) A Review of Pharmacotherapy for Chronic Low Back Pain with Considerations for Sports Medicine. The Physician and Sportsmedicine 40:4, pages 21-32.
Read now
Read now
Sebastiano Mercadante. (2011) The use of high doses of OROS hydromorphone in an acute palliative care unit. Current Medical Research and Opinion 27:12, pages 2373-2376.
Read now
Read now
Robert L. Barkin, Stacy J. Barkin, Gordon A. Irving & Allan Gordon. (2011) Management of Chronic Noncancer Pain in Depressed Patients. Postgraduate Medicine 123:5, pages 143-154.
Read now
Read now
Harold W Goforth. (2010) Hydromorphone-OROS formulation. Expert Opinion on Pharmacotherapy 11:7, pages 1207-1214.
Read now
Read now
J Turgeon, R Gröning, G Sathyan, J Thipphawong & U Richarz. (2010) The pharmacokinetics of a long-acting OROS hydromorphone formulation. Expert Opinion on Drug Delivery 7:1, pages 137-144.
Read now
Read now
Sharon M Weinstein. (2009) A new extended release formulation (OROS) of hydromorphone in the management of pain. Therapeutics and Clinical Risk Management 5, pages 75-80.
Read now
Read now
Lynn R Webster, Brad Bath & Robert A Medve. (2009) Opioid formulations in development designed to curtail abuse: who is the target?. Expert Opinion on Investigational Drugs 18:3, pages 255-263.
Read now
Read now
Articles from other publishers (35)
Francesco Traccis, Riccardo Presciuttini, Pier Paolo Pani, Julia M.A. Sinclair, Lorenzo Leggio & Roberta Agabio. (2022) Alcohol-medication interactions: A systematic review and meta-analysis of placebo-controlled trials. Neuroscience & Biobehavioral Reviews 132, pages 519-541.
Crossref
Crossref
Nils Burger, Douglas Fraser, Martina Alice Maritz, Janice Faulkner & Helene Rey. (2020) Once‐Daily Oxycodone Prolonged‐Release Tablets Are Resistant to Alcohol‐Induced Dose Dumping: Results From a Randomized Trial in Healthy Volunteers. Clinical and Translational Science 13:3, pages 539-546.
Crossref
Crossref
Mariangela Rondanelli, Milena Anna Faliva, Alessandra Miccono, Maurizio Naso, Mara Nichetti, Antonella Riva, Fabio Guerriero, Manuela De Gregori, Gabriella Peroni & Simone Perna. (2018) Food pyramid for subjects with chronic pain: foods and dietary constituents as anti-inflammatory and antioxidant agents. Nutrition Research Reviews 31:1, pages 131-151.
Crossref
Crossref
Susan D’Souza, Stephen Mayock & Alger Salt. (2017) A review of in vivo and in vitro aspects of alcohol-induced dose dumping. AAPS Open 3:1.
Crossref
Crossref
Charlotte Martin, Andy De Baerdemaeker, Jan Poelaert, Annemieke Madder, Richard Hoogenboom & Steven Ballet. (2016) Controlled-release of opioids for improved pain management. Materials Today 19:9, pages 491-502.
Crossref
Crossref
Amy Peacock, Raimondo Bruno, Briony Larance, Nick Lintzeris, Suzanne Nielsen, Robert Ali, Timothy Dobbins & Louisa Degenhardt. (2016) Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study. Drug and Alcohol Dependence 166, pages 125-133.
Crossref
Crossref
A. Mercuri, R. Fares, M. Bresciani & N. Fotaki. (2016) An in vitro–in vivo correlation study for nifedipine immediate release capsules administered with water, alcoholic and non-alcoholic beverages: Impact of in vitro dissolution media and hydrodynamics. International Journal of Pharmaceutics 499:1-2, pages 330-342.
Crossref
Crossref
Kaoru Toyama, Naoki Uchida, Hitoshi Ishizuka, Takehiko Sambe & Shinichi Kobayashi. (2015) Single-dose evaluation of safety, tolerability and pharmacokinetics of newly formulated hydromorphone immediate-release and hydrophilic matrix extended-release tablets in healthy Japanese subjects without co-administration of an opioid antagonist. The Journal of Clinical Pharmacology 55:9, pages 975-984.
Crossref
Crossref
N. Jedinger, S. Schrank, S. Mohr, A. Feichtinger, J. Khinast & E. Roblegg. (2015) Alcohol dose dumping: The influence of ethanol on hot-melt extruded pellets comprising solid lipids. European Journal of Pharmaceutics and Biopharmaceutics 92, pages 83-95.
Crossref
Crossref
N. Jedinger, J. Khinast & E. Roblegg. (2014) The design of controlled-release formulations resistant to alcohol-induced dose dumping – A review. European Journal of Pharmaceutics and Biopharmaceutics 87:2, pages 217-226.
Crossref
Crossref
Beatrice Setnik, Marta Sokolowska, Franklin Johnson, John Oldenhof & Myroslava Romach. (2014) Evaluation of the safety, pharmacodynamic, and pharmacokinetic effects following oral coadministration of immediate-release morphine with ethanol in healthy male participants. Human Psychopharmacology: Clinical and Experimental 29:3, pages 251-265.
Crossref
Crossref
Krishna Devarakonda, Joris Vandenbossche & Ute Richarz. (2013) Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing. SpringerPlus 2:1.
Crossref
Crossref
F.J.O. Varum, G.B. Hatton & A.W. Basit. (2013) Food, physiology and drug delivery. International Journal of Pharmaceutics 457:2, pages 446-460.
Crossref
Crossref
Thomas B. Gregory. (2013) Hydromorphone: Evolving to Meet the Challenges of Today’s Health Care Environment. Clinical Therapeutics 35:12, pages 2007-2027.
Crossref
Crossref
Kiyohiko Sugano. 2012. Biopharmaceutics Modeling and Simulations. Biopharmaceutics Modeling and Simulations
379
411
.
Ricardo A. Cruciani, Nathaniel Katz & Russell K. Portenoy. (2012) Dose Equivalence of Immediate-Release Hydromorphone and Once-Daily Osmotic-Controlled Extended-Release Hydromorphone: A Randomized, Double-Blind Trial Incorporating a Measure of Assay Sensitivity. The Journal of Pain 13:4, pages 379-389.
Crossref
Crossref
Frank Porecca & Tamara KingMellar P Davis. 2012. Analgesics for Cancer Pain. Analgesics for Cancer Pain
42
59
.
William D. Fiske, Janet Jobes, Qinfang Xiang, Sou-Chan Chang & Irma H. Benedek. (2012) The Effects of Ethanol on the Bioavailability of Oxymorphone Extended-Release Tablets and Oxymorphone Crush-Resistant Extended-Release Tablets. The Journal of Pain 13:1, pages 90-99.
Crossref
Crossref
Johann D. Ringe, Susanne Schäfer, Antonie M. Wimmer & Thorsten Giesecke. (2011) Use of OROS® hydromorphone in the treatment of osteoarthritis and osteoporosis: A pooled analysis of three non-interventional studies focusing on different starting dosesAnwendung von OROS® Hydromorphon in der Behandlung von Arthrose- und Osteoporoseschmerzen; eine gepoolte Analyse von drei nicht-interventionellen Studien mit verschiedenen Startdosen. Wiener klinische Wochenschrift 124:1-2, pages 25-31.
Crossref
Crossref
Kenneth Todd Moore, Dominique St-Fleur, Nadia Cardillo Marricco, Jay Ariyawansa, Véronique Pagé, Jayalakshmi Natarajan, Gaetano Morelli & Ute Richarz. (2011) A Randomized Study of the Effects of Food on the Pharmacokinetics of Once-Daily Extended-Release Hydromorphone in Healthy Volunteers. The Journal of Clinical Pharmacology 51:11, pages 1571-1579.
Crossref
Crossref
David R. P. Guay. (2010) Oral Hydromorphone Extended-Release. The Consultant Pharmacist 25:12, pages 816-828.
Crossref
Crossref
Ira Whitten. 2010. The Essence of Analgesia and Analgesics. The Essence of Analgesia and Analgesics
448
451
.
Anjanette P. Smith, Terry W. Moore, Benjamin J. Westenberger & William H. Doub. (2010) In vitro dissolution of oral modified-release tablets and capsules in ethanolic media. International Journal of Pharmaceutics 398:1-2, pages 93-96.
Crossref
Crossref
Robert B. Raffa & Joseph V. PergolizziJrJr. (2010) Opioid Formulations Designed to Resist/Deter Abuse. Drugs 70:13, pages 1657-1675.
Crossref
Crossref
Michael J. Brennan & Steven Stanos. (2010) Strategies to Optimize Pain Management With Opioids While Minimizing Risk of Abuse. PM&R 2:6, pages 544-558.
Crossref
Crossref
David Lussier, Ute Richarz & Gabriele Finco. (2010) Use of Hydromorphone, with Particular Reference to the OROS® Formulation, in the Elderly. Drugs & Aging 27:4, pages 327-335.
Crossref
Crossref
Natalie J. Carter & Gillian M. Keating. (2010) OROS® Hydromorphone Prolonged Release. CNS Drugs 24:4, pages 337-361.
Crossref
Crossref
Jackie Gardner-Nix & Sebastiano Mercadante. (2010)
The Role of OROS
®
Hydromorphone in the Management of Cancer Pain
. Pain Practice 10:1, pages 72-77.
Crossref
Crossref
Magdi Hanna, Alberto Tuca & John Thipphawong. (2009) An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS® hydromorphone in patients with chronic cancer pain. BMC Palliative Care 8:1.
Crossref
Crossref
Robert L Barkin, Dean Shirazi & Eric Kinzler. (2009) Effect of Ethanol on the Release of Morphine Sulfate From Oramorph SR Tablets. American Journal of Therapeutics 16:6, pages 482-486.
Crossref
Crossref
Hans Lennernäs. (2009) Ethanol−Drug Absorption Interaction: Potential for a Significant Effect on the Plasma Pharmacokinetics of Ethanol Vulnerable Formulations. Molecular Pharmaceutics 6:5, pages 1429-1440.
Crossref
Crossref
Jay S Grider. (2009) Clinical application of extended-release hydromorphone for pain management. Therapy 6:5, pages 653-656.
Crossref
Crossref
Howard S. Smith. (2009) Enteral Controlled-Release Opioid Delivery Systems. Pain Medicine 10:suppl 1, pages S30-S38.
Crossref
Crossref
Magdi Hanna & John Thipphawong. (2008) A randomized, double-blind comparison of OROS®hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care 7:1.
Crossref
Crossref
Donna A. Volpe, Ebenezer B. Asafu-Adjaye, Christopher D. Ellison, Suresh Doddapaneni, Ramana S. Uppoor & Mansoor A. Khan. (2008) Effect of Ethanol on Opioid Drug Permeability Through Caco-2 Cell Monolayers. The AAPS Journal 10:2, pages 360-362.
Crossref
Crossref